Jason R Young Selected Research

Langerhans Cell Sarcoma

1/2022

Prolonged remission with pembrolizumab and radiation therapy in a patient with multisystem Langerhans cell sarcoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jason R Young Research Topics

Disease

5	Neoplasms (Cancer) 01/2022 - 04/2019
3	Erdheim-Chester Disease 01/2022 - 01/2018
3	Corneal Neovascularization 12/2012 - 04/2012
2	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 01/2020
2	Langerhans-Cell Histiocytosis (Histiocytosis, Langerhans Cell) 01/2021 - 12/2020
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2021 - 11/2020
2	Inflammation (Inflammations) 12/2012 - 02/2012
1	Hypoxia (Hypoxemia) 11/2022
1	Gastroesophageal Reflux (GERD) 11/2022
1	Hyperplasia 11/2022
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022
1	Langerhans Cell Sarcoma 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022
1	Hemorrhage 12/2021
1	COVID-19 11/2021
1	Neurolymphomatosis 01/2021
1	Adenoma (Adenomas) 01/2021
1	Liver Cell Adenoma (Hepatocellular Adenoma) 01/2021
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021
1	Carcinoid Tumor (Carcinoid) 11/2020
1	Rheumatoid Nodule 04/2019
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Hip Fractures (Intertrochanteric Fractures) 07/2012
1	Type 2 Diabetes Mellitus (MODY) 01/2010
1	Weight Gain 01/2010
1	Hypoglycemia (Reactive Hypoglycemia) 01/2010

Drug/Important Bio-Agent (IBA)

3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021 - 01/2018
2	gallium Ga 68 dotatateIBA 01/2021 - 11/2020
2	SteroidsIBA 12/2012 - 04/2012
2	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 12/2012 - 04/2012
1	InterleukinsIBA 11/2022
1	AcidsIBA 11/2022
1	CausticsIBA 11/2022
1	pembrolizumabIBA 01/2022
1	pexidartinibIBA 01/2022
1	Mitogen-Activated Protein KinasesIBA 01/2022
1	Chimeric Antigen ReceptorsIBA 01/2022
1	AnticoagulantsIBA 12/2021
1	VaccinesIBA 11/2021
1	LutetiumIBA 01/2021
1	brexucabtagene autoleucelIBA 01/2021
1	Radioisotopes (Radionuclides)IBA 01/2021
1	Cladribine FDA LinkGeneric 01/2021
1	Peptide Receptors (Peptide Receptor)IBA 01/2021
1	Somatostatin Receptors (Somatostatin Receptor)IBA 11/2020
1	VemurafenibIBA 11/2020
1	Rheumatoid FactorIBA 04/2019
1	Technetium Tc 99m MedronateIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	GlucocorticoidsIBA 12/2012
1	SuspensionsIBA 12/2012
1	Antipsychotic Agents (Antipsychotics)IBA 07/2012
1	Antidepressive Agents (Antidepressants)IBA 07/2012
1	RNA Precursors (Precursor, mRNA)IBA 02/2012
1	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 02/2012
1	MorpholinosIBA 02/2012
1	Long-Acting Insulin (Insulin, Long Acting)FDA Link 01/2010
1	Isophane Insulin (NPH Insulin)FDA Link 01/2010
1	Insulin Detemir (Levemir)FDA Link 01/2010
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2010
1	Insulin (Novolin)FDA Link 01/2010
1	Insulin Glargine (Lantus)FDA Link 01/2010

Therapy/Procedure

11	Therapeutics 01/2022 - 04/2012
3	Penetrating Keratoplasty 12/2012 - 04/2012
2	Drug Therapy (Chemotherapy) 01/2022 - 01/2022
2	Sutures (Suture) 12/2012 - 02/2012
1	Radiotherapy 01/2022
1	Combined Modality Therapy 01/2022
1	Injections 12/2012
1	Glycemic Control 01/2010